Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
13F holders, Q4 2021
Institutional positions in Jasper Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +1 vs. Q3 2021
- Shares held
- 1.45M
- −305.6K (−17.4%) vs. Q3 2021
- Total value
- $2.97M
- −$522.0K (−14.9%) vs. Q3 2021
- New holders
- 7
- 0 more added
- Sold out
- 6
- 6 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JSPRW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $187.1K |
| Q1 2026 | 8 | $371.6K |
| Q4 2025 | 10 | $761.1K |
| Q3 2025 | 9 | $1.09M |
| Q2 2025 | 7 | $383.1K |
| Q1 2025 | 6 | $129.0K |
| Q4 2024 | 5 | $193.1K |
| Q3 2024 | 5 | $625.7K |
| Q2 2024 | 5 | $618.9K |
| Q1 2024 | 4 | $538.5K |
| Q4 2023 | 6 | $236.3K |
| Q3 2023 | 8 | $120.7K |
| Q2 2023 | 11 | $344.6K |
| Q1 2023 | 11 | $430.9K |
| Q4 2022 | 15 | $55.5K |
| Q3 2022 | 15 | $135.0K |
| Q2 2022 | 15 | $179.0K |
| Q1 2022 | 16 | $554.0K |
| Q4 2021 | 16 | $2.97M |
| Q3 2021 | 16 | $3.67M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Jasper Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Highbridge Capital Management LLC | – | $825.0K | 0.02% | – | – |
| Owl Creek Asset Management, L.P. | 374,833 | $551.0K | 0.04% | −297,224−44.2% | Reduced |
| Ionic Capital Management LLC | 338,676 | $498.0K | 0.09% | +338,676 | New |
| Tenor Capital Management Co., L.P. | 250,000 | $368.0K | 0.01% | 00.0% | Unchanged |
| Shaolin Capital Management LLC | 128,572 | $189.0K | 0.00% | −76,689−37.4% | Reduced |
| Privium Fund Management B.V. | 98,011 | $153.0K | 0.03% | +98,011 | New |
| Rivernorth Capital Management, LLC | 65,707 | $97.0K | 0.00% | −23,889−26.7% | Reduced |
| Integrity Capital Management (HK) Ltd | 50,000 | $74.0K | 0.24% | +50,000 | New |
| Equitec Proprietary Markets, LLC | 45,856 | $67.0K | 0.04% | +45,856 | New |
| HRT Financial LP | 37,045 | $54.0K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 25,059 | $37.0K | 0.00% | −55,625−68.9% | Reduced |
| Walleye Trading LLC | 14,095 | $21.0K | 0.00% | −26,758−65.5% | Reduced |
| Yakira Capital Management, Inc. | 11,705 | $17.0K | 0.00% | −11,295−49.1% | Reduced |
| Wolverine Asset Management LLC | 8,394 | $12.0K | 0.00% | +8,394 | New |
| UBS Group AG | 4,762 | $7.00K | 0.00% | +4,762 | New |
| SkyView Investment Advisors, LLC | 2 | $0 | 0.00% | +2 | New |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −179,723−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Bulldog Investors, LLP | 0 | $0 | 0.00% | −47,887−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −11,988−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −10,200−100.0% | Sold out |
| Easterly Investment Partners LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Zazove Associates LLC | – | – | – | – | Not filed |